Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung
- 17 November 2018
- journal article
- research article
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 35 (7-8) , 415-421
Abstract
Anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and alectinib have been shown to have significant activity in ALK-rearranged non-small cell lung cancers (NSCLC). There are no data for alectinib’s safety or efficacy in younger patients, though it is superior to crizotinib in adult trials. We present a 14-year old girl diagnosed with stage IV-B ALK-positive adenocarcinoma of the lung after presenting with cough and fever. She was commenced on alectinib at adult dose and has had sustained complete metabolic remission for 9 months. She is the youngest patient with lung adenocarcinoma to be treated with alectinib.Keywords
Funding Information
- Leukaemia Research Support Fund
This publication has 22 references indexed in Scilit:
- Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2018
- Treatment of ALK-positive nonsmall cell lung cancer: recent advancesCurrent Opinion in Oncology, 2018
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group StudyJournal of Clinical Oncology, 2017
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialThe Lancet, 2017
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyThe Lancet, 2017
- The Eighth Edition Lung Cancer Stage ClassificationChest, 2017
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009